Echelon Biosciences echelon-inc.com


Public list: Pharma Startups (4740) Cancer Therapeutics (1146)

Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brai...Show all

Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activa...Show all

Company (Alive / Active)

Phone: 801-588-0455

Fax:

675 Arapeen Dr Suite 302
Suite 32
Salt Lake City, 84108
Utah, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Echelon Biosciences $0.2M Jan 11, 2010
See all 55 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Echelon Biosciences Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Cognition Therapeutics

Pittsburgh, Pennsylvania, United States
Alive / ActiveCognition Therapeutics is focused on the discovery and development of small molecule therapeutics targeting toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other degenerative diseases of the human brain. Toxic proteins play a crucial role in a large number of human diseases, and there are currently no therapeutics available to prevent toxic protein accumulation or block their destructive effects. Cognition is founded on the combination of biological expert...Show allLogin to see details

Ensoltek

South Korea
Alive / ActiveEnsoltek is working on making drug discovery cheaper, much cheaper. The idea is to simulate how proteins and enzymes interact in the human body by duplicating the experiment in silico""that is, in a computer""as opposed to in vivo""a living creature.Login to see details
See all 55 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Compounds and methods of use thereof for assaying lysophospholipase d activity May 12, 2010 Aug 20, 2013 Patent
Compounds and methods of use thereof for assaying lysophospholipase d activity Oct 28, 2008 Aug 02, 2011 Patent